Preplanned Studies

The Association Between Preserved Ratio Impaired Spirometry and Mortality — 10 CKB Study Areas, China, 2004–2022

Yalei Ke¹; Xinyi Zhang¹; Dianjianyi Sun¹.².³; Pei Pei²; Huaidong Du⁴; Yiping Chen⁴; Ling Yang⁴; Xiaoming Yang⁴; Kang Wang⁵; Junshi Chen⁶; Zhengming Chen⁴; Jun Lv¹.².³; Liming Li¹.².³; Canqing Yu¹.².³.#

Summary

What is already known about this topic?

China has the world's most significant public health and economic burden of chronic respiratory disease. However, the association between preserved ratio impaired spirometry (PRISm) and mortality risk is unknown.

What is added by this report?

The PRISm group exhibited a 37% higher risk of all-cause mortality than the normal group, and the risks of death from cardiovascular diseases, neoplasms, respiratory diseases, and infectious and parasitic diseases were also increased in PRISm. Moreover, the presence of respiratory symptoms or disease was associated with an increased risk of mortality in PRISm.

What are the implications for public health practice?

It is imperative to enhance public awareness of PRISm and to implement measures to facilitate the regression of PRISm toward normal lung function.

Preserved ratio impaired spirometry (PRISm) is a non-obstructive spirometry phenotype described as a transient state associated with the progression of chronic obstructive pulmonary disease (COPD) (1). The prevalence of COPD is increasing in China (2). Previous studies excluded PRISm from respiratory studies (3), while recent studies on PRISm have predominantly been conducted in Western or highincome countries (1), leaving the significance of this lung function pattern in China uncertain. To address these gaps, this study analyzed the association between PRISm and all-cause and cause-specific mortality based on the China Kadoorie Biobank (CKB), a large-scale prospective cohort. Elevated risks of mortality from allcause, cardiovascular, neoplastic, respiratory, and infectious and parasitic diseases were observed in PRISm, with rates comparable to those observed in obstructive spirometry. PRISm should be given more attention to avoid its progression to COPD.

The CKB, which has been reported previously (4), recruited 512,724 participants aged 30 to 79 from 10 areas across China at baseline from 2004 to 2008. All individuals underwent interviewer-administered questionnaires, physical measurements, and spirometry tests by trained technicians according to standard operating procedures. In the present study, participants with previously self-reported physician-diagnosed ischemic heart disease, stroke, cancer, or asthma at baseline, lost to follow-up shortly after baseline, with an FEV₁/FVC ratio >1.0, or missing data for covariates were omitted from the study, leaving 484,301 participants.

For baseline spirometry, the higher of two measurements for both FEV1 and FVC was used to calculate the FEV $_1$ /FVC ratio. Predicted FEV $_1$ was calculated using the Global Lung Function Initiative 2012 equations for the Southeast Asian and Northeast Asian populations (5). Normal lung function was defined as an FEV $_1$ /FVC ratio \geq 0.7 and FEV $_1$ \geq 80% predicted, PRISm as an FEV $_1$ /FVC ratio \geq 0.7 and FEV $_1$ \leq 80% predicted, and obstructive spirometry as an FEV $_1$ /FVC ratio \leq 0.7.

Mortality data were obtained from official residential records and the Disease Surveillance Points system, supplemented by annual door-to-door investigations among those not linked to the database. Based on the International Classification of Disease, 10th Revision (ICD-10), the outcomes comprised death from all and cause-specific mortality, including circulatory diseases (ICD-10: I00-I99), neoplasms (C00–D48), respiratory diseases (J00–J99), infectious and parasitic diseases (A00-B99), ischemic heart disease (I20-I25), intracerebral hemorrhage (I61), ischemic stroke (I63), lung cancer (C34), COPD (J41–J44), pneumonia (J12–J18), and respiratory tuberculosis (A15-A16). Participants were censored upon death, loss to follow-up, or December 31, 2022, whichever occurred first.

Baseline variable means and prevalences were calculated for normal, PRISm, and obstructive

spirometry groups using linear regression continuous variables and logistic regression categorical variables, adjusted for age, sex, and 10 study areas when appropriate. Mortality rates per 100,000 person-years for each group were standardized to the age structure of the 7th National Population Census data (2020). For all-cause mortality, stratified Cox proportional hazards regression was used to estimate hazard ratios (HRs) with 95% confidence intervals proportional subdistribution regression model for cause-specific mortality was fitted to account for competing risks from other causes. All analyses were stratified by age (in 5-year groups), sex, and 10 study areas, and adjusted for education, occupation, household income, marital status, alcohol consumption, smoking status, passive smoking status, physical activity levels, primary cooking and heating fuel use, consumption frequency of fresh fruits, fresh vegetables, and meat, general obesity, and abdominal obesity. The proportional hazards assumption was verified using Schoenfeld residuals. Associations between mortality and PRISm were analyzed after stratification by the presence of self-reported cough or sputum, ever-smoking, physician-diagnosed bronchitis or emphysema, and tuberculosis at baseline. Subgroup analyses were conducted across sex, age (≥60 years or not), and region (urban/rural).

Competing-risk analysis was performed using SAS (version 9.4, SAS Institute Inc, Cary, NC, USA), and all other statistical analyses were performed using R (version 4.3.1, R Foundation for Statistical Computing, Vienna, Austria). All tests were two-tailed, and *P*<0.05 were considered statistically significant.

The study included 484,301 participants with a mean age of 51.5 [standard deviation (SD)=10.5] years at baseline, 59.1% women, and 32.3% ever-smokers. At baseline, 117,210 (24.2%) had PRISm, with a mean FEV₁ % predicted of 83.9%. Compared with the normal group, individuals with PRISm or an obstructive spirometry pattern were more likely to be older, male, current or former smokers, reside in rural areas, have a lower socioeconomic level, and report poorer self-rated health status (Table 1).

During a median follow-up of 16.0 years, 73,288 deaths were documented, and the corresponding all-cause age-standardized mortality rates for normal, PRISm, and obstructive spirometry were 1,070.5, 1,574.4, and 1,943.3 per 100,000 person-years, respectively. Compared with the normal group, PRISm had a higher adjusted all-cause (*HR*=1.37, 95% *CI*: 1.35, 1.40), circulatory disease [subdistribution hazard

ratio (SHR)=1.36, 95% CI: 1.33, 1.40], neoplasm (SHR=1.07, 95% CI: 1.04, 1.11), and infectious and parasitic disease (SHR=1.47, 95% CI: 1.24, 1.73) mortality, comparable to those observed in obstructive spirometry (Table 2). For respiratory disease mortality, the SHR in PRISm was 2.45 (95% CI: 2.30, 2.60), than those with obstructive spirometry (SHR=5.05, 95% CI: 4.73, 5.39). For disease-specific deaths, PRISm was associated with a higher risk of death from ischemic heart disease (SHR=1.37, 95% CI: 1.31, 1.42), intracerebral hemorrhage (SHR=1.31, 95% CI: 1.25, 1.38), ischemic stroke (SHR=1.30, 95% CI: 1.20, 1.40), lung cancer (SHR=1.26, 95% CI: 1.19, 1.34), COPD (SHR=3.06, 95% CI: 2.84, 3.31), pneumonia (SHR=1.47, 95% CI: 1.28, 1.68), and respiratory tuberculosis (SHR=2.63, 95% CI: 1.82, 3.82).

When stratified by respiratory symptoms of PRISm individuals, those with frequent coughing or sputum (HR=1.62, 95% CI: 1.57, 1.68) and self-reported prior bronchitis or emphysema (HR=1.81, 95% CI: 1.72, 1.91) had a much higher risk of all-cause mortality. However, the risk of all-cause mortality in the PRISm group did not appear to be substantially affected by smoking or passive smoking status (Figure 1). Analyses of sex, age, and regional subgroups of PRISm mortality risk did not show large differences (Supplementary Table S1, available at https://weekly.chinacdc.cn/).

DISCUSSION

Based on a large prospective cohort, this study explored the health effects of PRISm in the Chinese population, examining a comprehensive spectrum of mortality risks. The PRISm group exhibited a 1.4-fold higher risk of all-cause mortality. Risks of cause-specific death were also increased in the PRISm group; however, respiratory disease mortality in the PRISm group was lower than in the obstructive spirometry group, suggesting the reversibility of airflow obstruction development in PRISm. Moreover, respiratory-related symptoms and diseases were associated with an increased mortality risk, which could help identify high-risk individuals in the PRISm population.

A systematic review, including eight populationbased cohort studies up to 2023, found that PRISm was associated with a 1.7-fold, 1.6-fold, and 2.0-fold increased risk of all-cause, cardiovascular, and respiratory mortality, respectively (1). These results were slightly higher than our findings; however, the

TABLE 1. Characteristics of China Kadoorie Biobank participants by obstruction state at baseline of 2004–2008.

Characteristics	Normal	PRISm	Obstructive spirometry
No. of participants	341,975 (70.6)	117,210 (24.2)	25,116 (5.2)
FEV ₁ /FVC [%, mean (SD)]	86.3 (5.8)	83.9 (5.9)	64.4 (5.8)
FEV ₁ % predicted [%, mean (SD)]	96.1 (11.1)	69.8 (11.3)	62.0 (11.2)
Sociodemographic characteristics			
Age, years [mean (SD)]	50.5 (10.4)	53.0 (10.6)	58.8 (10.4)
Women	59.5	59.9	50.8
Urban	44.9	40.5	29.0
South	64.8	46.4	72.8
Education >6 years	50.4	46.1	45.1
Farmer or worker	57.5	57.9	58.7
Household income ≥20,000 yuan/year	43.9	40.3	35.7
Married	91.3	90.4	89.1
Lifestyle factors			
Ever smoking	31.8	32.8	36.3
Ever passive smoking	75.5	75.7	73.8
Currently drinking	15.3	14.7	14.2
Daily intake of fresh fruit	18.6	17.1	16.8
Daily intake of fresh vegetables	94.9	94.3	94.4
>4 days/week intake meat	47.6	46.8	43.9
Physical activity, MET-h/d [mean (SD)]	21.7 (12.2)	21.2 (12.5)	21.3 (12.3)
BMI, kg/m² [mean (SD)]	23.6 (3.3)	23.8 (3.4)	22.5 (3.3)
Abdominal obesity	22.2	28.3	15.8
Personal medical history			
Self-rated poor health	8.3	10.5	13.9
Hypertension	32.7	37.5	30.5
Diabetes	5.2	6.1	4.4
Emphysema or bronchitis	1.4	3.4	8.9
Frequent coughing	6.9	9.6	15.0
Frequent expectoration	6.2	8.5	13.0

Note: Values are reported as % unless otherwise indicated and adjusted for age, sex, and study areas when appropriate. All P values for comparisons between groups were < 0.001, except for ever passive smoking (P=0.009). Lung function category definitions: normal (FEV_1/FVC ratio \geq 0.7 and $FEV_1 \geq$ 80%), PRISm (FEV_1/FVC ratio \geq 0.7 and $FEV_1 \leq$ 80%), and obstructive spirometry (FEV_1/FVC ratio \leq 0.7). Abbreviation: PRISm=preserved ratio impaired spirometry; FEV_1 =forced expiratory volume in one second; FVC=forced vital capacity; SD=standard deviation; MET-h/d=metabolic equivalents of task per hour per day; BMI=body mass index; CVD=cardiovascular disease.

review neglected the competing risks from other causes of death, leading to overestimation of the *HR*s. Evidence for disease-specific mortality risk is scarce due to the need for long-term follow-up and large sample sizes. Only one study reported that PRISm was associated with a 1.5-fold increased risk of death from stroke or heart disease (6). This study is the first to show that PRISm is associated with an increased risk of death from lung cancer, pneumonia, COPD, and respiratory tuberculosis. However, no modification effect was observed between smoking or passive

smoking and the association between PRISm and mortality. Nonetheless, previous studies have shown smoking to be a strong risk factor for PRISm and its progression to airflow obstruction (7,8), suggesting that smoking cessation should be prioritized when managing PRISm to prevent premature death.

This study has several limitations. First, like other population-based epidemiologic studies (7,9), spirometry without postbronchodilator testing may overestimate the prevalence of both PRISm and obstructive spirometry. Participants with self-reported

TABLE 2. Associations of PRISm and Obstructive Spirometry with all-cause and cause-specific mortality in China Kadoorie Biobank, 2004–2022.

Cause of death	Normal	PRISm	Obstructive spirometry	
All causes				
No. of deaths (mortality rate)	40,099 (1,070.5)	23,791 (1,574.4)	9,398 (1,943.3)	
HR (95% CI)	1.00	1.37 (1.35, 1.40)	1.59 (1.56, 1.63)	
Circulatory diseases				
No. of deaths (mortality rate)	16,091 (473.7)	10,916 (738.0)	3,340 (676.2)	
SHR (95% CI)	1.00	1.36 (1.33, 1.40)	1.22 (1.18, 1.27)	
Ischemic heart disease				
No. of deaths (mortality rate)	6,008 (181.1	4,254 (293.2)	1,157 (250.0)	
SHR (95% CI)	1.00	1.37 (1.31, 1.42)	1.22 (1.14, 1.30)	
Intracerebral haemorrhage				
No. of deaths (mortality rate)	3,726 (96.7)	2,938 (186.6)	881 (169.7)	
SHR (95% <i>CI</i>)	1.00	1.31 (1.25, 1.38)	1.29 (1.19, 1.39)	
Ischemic stroke				
No. of deaths (mortality rate)	1,808 (61.0)	1,198 (84.5)	329 (64.8)	
SHR (95% CI)	1.00	1.30 (1.20, 1.40)	1.02 (0.90, 1.15)	
Neoplasms				
No. of deaths (mortality rate)	13,982 (316.1)	6,188 (374.5)	2,231 (461.3)	
SHR (95% CI)	1.00	1.07 (1.04, 1.11)	1.09 (1.04, 1.14)	
Lung cancer				
No. of deaths (mortality rate)	3,416 (77.4)	1,843 (111.8)	692 (134.8)	
SHR (95% CI)	1.00	1.26 (1.19, 1.34)	1.35 (1.24, 1.48)	
Respiratory diseases				
No. of deaths (mortality rate)	2,013 (69.6)	2,607 (188.5)	2,389 (481.3)	
SHR (95% CI)	1.00	2.45 (2.30, 2.60)	5.05 (4.73, 5.39)	
COPD				
No. of deaths (mortality rate)	1,148 (39.6)	2,009 (146.1)	2,130 (426.8)	
SHR (95% CI)	1.00	3.06 (2.84, 3.31)	6.81 (6.29, 7.38)	
Pneumonia				
No. of deaths (mortality rate)	582 (21.2)	380 (27.6)	125 (26.7)	
SHR (95% CI)	1.00	1.47 (1.28, 1.68)	1.32 (1.08, 1.63)	
Infectious and parasitic diseases				
No. of deaths (mortality rate)	445 (10.8)	275 (16.8)	101 (22.3)	
SHR (95% CI)	1.00	1.47 (1.24, 1.73)	1.68 (1.33, 2.11)	
Respiratory tuberculosis				
No. of deaths (mortality rate)	59 (1.5)	69 (4.9)	48 (10.2)	
SHR (95% CI)	1.00	2.63 (1.82, 3.82)	4.08 (2.69, 6.19)	
Other diseases				
No. of deaths (mortality rate)	7,568 (200.3)	3,805 (256.6)	1,337 (302.2)	
SHR (95% CI)	1.00	1.23 (1.18, 1.28)	1.15 (1.08, 1.22)	

Note: The mortality rate is per 100,000 person-years and is age-standardized based on the 7^{th} National Population Census data (2020). For cause-specific mortality, other causes of mortality were considered as competing risks, and SHRs were calculated. HRs and SHRs were stratified by age (in 5-year intervals), sex, and study areas, and adjusted for education, occupation, household income, marital status, alcohol consumption, smoking status, passive smoking status, physical activity levels, cooking and heating fuel usage, consumption frequency of fresh fruits, fresh vegetables, meat, and general and abdominal obesity. Lung function category definitions: normal (FEV $_1$ /FVC ratio \geq 0.7 and FEV $_1$ \geq 80%), PRISm (FEV $_1$ /FVC ratio \geq 0.7 and FEV $_1$ \leq 80%), and obstructive spirometry (FEV $_1$ /FVC ratio \leq 0.7). Abbreviation: PRISm=preserved ratio impaired spirometry; COPD=chronic obstructive pulmonary disease; HR=hazard ratio;

SHR=subdistribution hazard ratio; CI=confidence interval; FEV₁=forced expiratory volume in one second; FVC=forced vital capacity.

Chinese Center for Disease Control and Prevention

Status	No. of deaths	Mortality rate	All c	ause of death	HR (95% CI)
PRISm + symptoms			1		
Normal	40,099	1,070.5	†		1.00
PRISm without symptoms	19,898	1,508.7	1	-	1.33 (1.31, 1.36)
PRISm with symptoms	3,893	2,049.1	1		1.62 (1.57, 1.68)
PRISm + smoking*			į		
Normal	40,099	1,070.5	Ť		1.00
PRISm non-smoker, no passive	3,051	1,314.2	;		1.40 (1.35, 1.46)
PRISm non-smoker, passive	9,494	1,340.3	1 1	-	1.37 (1.34, 1.41)
PRISm smoker	11,246	2,004.3	1	-=-	1.37 (1.34, 1.40)
PRISm + bronchitis or emphysema			į		
Normal	40,099	1,070.5	<u>†</u>		1.00
PRISm without bronchitis or emphysema	22,367	1,548.6	;	-	1.35 (1.33, 1.38)
PRISm with bronchitis or emphysema	1,424	2,195.7	1	-	1.81 (1.72, 1.91)
PRISm + tuberculosis			1		
Normal	40,099	1,070.5	Ť		1.00
PRISm without tuberculosis	23,104	1,570.2	į	-	1.37 (1.35, 1.39)
PRISm with tuberculosis	687	1,842.2			1.55 (1.43, 1.67)
			0.9 1.0	1.5	2.0

FIGURE 1. Associations of PRISm with symptoms, smoking, bronchitis or emphysema, tuberculosis at baseline with all-cause mortality in China Kadoorie Biobank, 2004–2022.

Note: The mortality rate is per 100,000 person-years and is age-standardized based on the 7th National Population Census data (2020). *HR*s were stratified by age (in 5-year intervals), sex, and study areas, and adjusted for education, occupation, household income, marital status, alcohol consumption, smoking status, passive smoking status, physical activity levels, cooking and heating fuel usage, consumption frequency of fresh fruits, fresh vegetables, meat, and general and abdominal obesity. Symptoms were defined as frequent coughing or sputum. PRISm was defined as FEV_1/FVC ratio ≥ 0.7 and $FEV_1 < 80\%$.

Abbreviation: PRISm=preserved ratio impaired spirometry; HR=hazard ratio; CI=confidence interval.

*PRISm individuals were grouped according to whether they never/occasionally smoked or smoked regularly, and whether they were passively exposed to smoke.

asthma at baseline were excluded to minimize such misclassification bias. Despite the potential misclassification, this study indicated that prebronchodilator testing is crucial and can provide significant insights, especially in resource-limited settings. Second, PRISm was employed as a single-time measurement of exposure. Given the high variability in spirometry-measured lung function observed within individuals over time (7,10), this study could not examine the relationship between longitudinal PRISm mortality trajectories and risk. Third. generalization of results to other populations should be made with caution, as the CKB cohort sample is not nationally representative.

This study identified an elevated risk of all-cause and cause-specific mortality from PRISm in China, including circulatory, neoplasm, respiratory, and infectious and parasitic disease mortality. This finding indicates the necessity of enhancing public awareness of PRISm and taking action to prevent its progression to COPD.

Conflicts of interest: No conflicts of interest.

Acknowledgements: The most important acknowledgement is to the participants in the study

and the members of the survey teams in each of the 10 regional centres, as well as to the project development and management teams based at Beijing, Oxford, and the 10 regional centres.

Funding: This work was supported by the National Natural Science Foundation of China (82388102, 82192900, 82192901, 82192904). The CKB baseline survey and the first re-survey were supported by a grant from the Kadoorie Charitable Foundation in Hong Kong. The long-term follow-up is supported by grants from the UK Wellcome Trust (212946/Z/18/Z, 202922/Z/16/Z, 104085/Z/14/Z, 088158/Z/09/Z), grants (2016YFC0900500) from the National Key R&D Program of China, National Natural Science Foundation of China (81390540, 91846303, 81941018), and Chinese Ministry of Science and Technology (2011BAI09B01). The funders had no role in the study design, data collection, data analysis and interpretation, writing of the report, or the decision to submit the article for publication.

doi: 10.46234/ccdcw2024.228

[#] Corresponding author: Canqing Yu, yucanqing@pku.edu.cn.

Department of Epidemiology and Biostatistics, School of Public Health, Peking University Health Science Center, Beijing, China;

Peking University Center for Public Health and Epidemic Preparedness & Response, Beijing, China; ³ Key Laboratory of Epidemiology of Major Diseases (Peking University), Ministry of Education, Beijing, China; ⁴ Clinical Trial Service Unit & Epidemiological Studies Unit (CTSU), Nuffield Department of Population Health, University of Oxford, Oxford, UK; ⁵ Shibei Center for Disease Control and Prevention, Qingdao City, Shandong Province, China; ⁶ China National Center for Food Safety Risk Assessment, Beijing, China; ⁷ State Key Laboratory of Vascular Homeostasis and Remodeling, Peking University, Beijing, China.

Submitted: July 03, 2024; Accepted: August 15, 2024

REFERENCES

- Yang SY, Liao GZ, Tse LA. Association of preserved ratio impaired spirometry with mortality: a systematic review and meta-analysis. Eur Respir Rev 2023;32(170):230135. https://doi.org/10.1183/16000617. 0135-2023.
- Wang C, Xu JY, Yang L, Xu YJ, Zhang XY, Bai CX, et al. Prevalence and risk factors of chronic obstructive pulmonary disease in China (the China Pulmonary Health [CPH] study): a national cross-sectional study. Lancet 2018;391(10131):1706 – 17. https://doi.org/10.1016/ S0140-6736(18)30841-9.
- Wan ES, Fortis S, Regan EA, Hokanson J, Han MK, Casaburi R, et al. Longitudinal phenotypes and mortality in preserved ratio impaired spirometry in the COPDGene study. Am J Respir Crit Care Med 2018;198(11):1397 – 405. https://doi.org/10.1164/rccm.201804-

- 0663OC.
- 4. Chen ZM, Chen JS, Collins R, Guo Y, Peto R, Wu F, et al. China Kadoorie Biobank of 0. 5 million people: survey methods, baseline characteristics and long-term follow-up. Int J Epidemiol 2011;40(6): 1652 66. https://doi.org/10.1093/ije/dyr120.
- Quanjer PH, Stanojevic S, Cole TJ, Baur X, Hall GL, Culver BH, et al. Multi-ethnic reference values for spirometry for the 3-95-yr age range: the global lung function 2012 equations. Eur Respir J 2012;40(6):1324 – 43. https://doi.org/10.1183/09031936.00080312.
- Shu CC, Tsai MK, Lee JH, Su TC, Wen CP. Mortality risk in patients with preserved ratio impaired spirometry: assessing the role of physical activity. QJM 2024;117(6):436 – 44. https://doi.org/10.1093/qjmed/ hcae010.
- Higbee DH, Granell R, Davey Smith G, Dodd JW. Prevalence, risk factors, and clinical implications of preserved ratio impaired spirometry: a UK Biobank cohort analysis. Lancet Respir Med 2022;10(2):149 – 57. https://doi.org/10.1016/S2213-2600(21)00369-6.
- Washio Y, Sakata S, Fukuyama S, Honda T, Kan-O K, Shibata M, et al. Risks of mortality and airflow limitation in Japanese individuals with preserved ratio impaired spirometry. Am J Respir Crit Care Med 2022;206(5):563 – 72. https://doi.org/10.1164/rccm.202110-2302OC.
- Wan ES, Balte P, Schwartz JE, Bhatt SP, Cassano PA, Couper D, et al. Association between preserved ratio impaired spirometry and clinical outcomes in US adults. JAMA 2021;326(22):2287 – 98. https://doi. org/10.1001/jama.2021.20939.
- Zheng JZ, Zhou R, Zhang YC, Su KL, Chen HW, Li FR, et al. Preserved ratio impaired spirometry in relationship to cardiovascular outcomes: a large prospective cohort study. Chest 2023;163(3):610 – 23. https://doi.org/10.1016/j.chest.2022.11.003.

SUPPLEMENTARY MATERIAL

SUPPLEMENTARY TABLE S1. Subgroup analysis of PRISm with all-cause and chapter-specific mortality in China Kadoorie Biobank, 2004–2022.

	All causes	Circulatory diseases	Neoplasms	Respiratory diseases	Infectious and parasitic diseases	Other
No. of deaths (mortality rate) HR	13,033 (1893.3) 1.37	5,637 (825.7) 1.32	3,711 (507.2) 1 11	1,526 (231.5) 2 38	185 (25.8) 1.58	1,974 (303.1) 1.18
(95% CI) No. of deaths (mortality rate) HR (95% CI)	(1.34, 1.40) 10,758 (1258.6) 1.37 (1.34, 1.41)	(1.28, 1.37) 5,279 (636.4) 1.40 (1.35, 1.46)	(1.06, 1.15) 2,477 (258.3) 1.03 (0.98, 1.08)	(2.20, 2.58) 1,081 (140.9) 2.55 (2.32, 2.80)	(1.28, 1.93) 90 (9.6) 1.29 (0.98, 1.70)	(1.12, 1.25) 1,831 (213.3) 1.29 (1.21, 1.37)
	,	,	,	,	,	,
No. of deaths (mortality rate)	8,400 (569.5)	3,278 (219.3)	2,751 (184.1) 1.07	588 (38.8) 3.50	144 (10.6) 1.67	1,639 (116.7) 1.37
(95% CI) No. of deaths (mortality rate) HR	(1.35, 1.43) 15,391 (4449.4) 1.36	(1.49, 1.63) 7,638 (2221.9) 1.29	(1.02, 1.12) 3,437 (919.1) 1.08	(3.08, 3.98) 2,019 (616.5) 2.15	(1.33, 2.09) 131 (34.8) 1.24	(1.29, 1.46) 2,166 (657.1) 1.13
(95% CI)	(1.33, 1.39)	(1.25, 1.33)	(1.03, 1.13)	(2.01, 2.30)	(0.98, 1.57)	(1.10, 1.20)
No. of deaths (mortality rate)	8,687 (1098.2)	3,711 (472.2)	2,685 (324.7)	752 (99.8)	83 (13.0)	1,456 (188.5)
(95% CI) No. of deaths (mortality rate) HR	(1.31, 1.38) 15,104 (2192.7) 1.39	(1.30, 1.42) 7,205 (1082.4) 1.36	(1.03, 1.13) 3,503 (435.2) 1.07	(1.83, 2.25) 1,855 (315.9) 2.74	(1.00, 1.73) 192 (23.3) 1.56	1.30 (1.21, 1.38) 2,349 (335.8) 1.19 (1.13, 1.25)
	(mortality rate) HR (95% CI) No. of deaths (mortality rate)	No. of deaths (1893.3) HR 1.37 (95% CI) (1.34, 1.40) No. of deaths (1258.6) HR 1.37 (95% CI) (1.34, 1.41) No. of deaths (1258.6) HR 1.37 (95% CI) (1.34, 1.41) No. of deaths (569.5) HR 1.39 (95% CI) (1.35, 1.43) No. of deaths (15,391) (mortality rate) (4449.4) HR 1.36 (95% CI) (1.33, 1.39) No. of deaths (95% CI) (1.31, 1.38) No. of deaths (1.34) (95% CI) (1.31, 1.38)	No. of deaths (13,033 5,637 (mortality rate) (1893.3) (825.7) (825.7) (1.37 1.32 (95% CI) (1.34, 1.40) (1.28, 1.37) (1.36 1.37 1.40 (95% CI) (1.34, 1.41) (1.35, 1.46) (95% CI) (1.34, 1.41) (1.35, 1.46) (95% CI) (1.34, 1.41) (1.35, 1.46) (95% CI) (1.35, 1.43) (1.49, 1.63) (1.49, 1.39) (1.25, 1.33) (1.25, 1.33) (1.25, 1.33) (1.25, 1.33) (1.25, 1.33) (1.25, 1.33) (1.30, 1.42) (1.31, 1.38) (1.30, 1.42) (1.31, 1.38) (1.30, 1.42) (1.31, 1.38) (1.30, 1.42) (1.39, 1.36) (1.39, 1.36)	No. of deaths (1893.3) (825.7) (507.2) (1.34, 1.40) (1.28, 1.37) (1.06, 1.15) (1.34, 1.41) (1.35, 1.46) (0.98, 1.08) (1.35, 1.43) (1.07, 1.32) (1.08, 1.07) (1.34, 1.41) (1.35, 1.46) (0.98, 1.08) (1.35, 1.43) (1.35, 1.43) (1.07, 1.32) (1.08, 1.07) (1.34, 1.41) (1.35, 1.46) (1.34, 1.41) (1.35, 1.46) (1.34, 1.41) (1.35, 1.46) (1.34, 1.41) (1.35, 1.46) (1.34, 1.41) (1.35, 1.46) (1.34, 1.41) (1.35, 1.46) (1.35	No. of deaths (mortality rate) 13,033 5,637 3,711 1,526 (mortality rate) (1893.3) (825.7) (507.2) (231.5) HR 1.37 1.32 1.11 2.38 (95% CI) (1.34, 1.40) (1.28, 1.37) (1.06, 1.15) (2.20, 2.58) No. of deaths 10,758 5,279 2,477 1,081 (mortality rate) (1258.6) (636.4) (258.3) (140.9) HR 1.37 1.40 1.03 2.55 (95% CI) (1.34, 1.41) (1.35, 1.46) (0.98, 1.08) (2.32, 2.80) No. of deaths 8,400 3,278 2,751 588 (mortality rate) (569.5) (219.3) (184.1) (38.8) HR 1.39 1.56 1.07 3.50 (95% CI) (1.35, 1.43) (1.49, 1.63) (1.02, 1.12) (3.08, 3.98) No. of deaths 15,391 7,638 3,437 2,019 (mortality rate) (4449.4) (2221.9) (919.1)	No. of deaths 13,033 5,637 3,711 1,526 185 (mortality rate) (1893.3) (825.7) (507.2) (231.5) (25.8) (25.8) (472.2) (4449.4) (2221.9) (95% CI) (1.33, 1.38) (1.25, 1.33) (1.03, 1.13) (2.01, 2.30) (0.98, 1.57) (1.03, 1.13) (2.01, 2.30) (0.98, 1.57) (1.06, 1.15) (2.20, 2.58) (1.28, 1.93) (1.06, 1.15) (2.20, 2.58) (1.28, 1.93) (1.06, 1.15) (2.20, 2.58) (1.28, 1.93) (1.06, 1.15) (2.20, 2.58) (1.28, 1.93) (1.06, 1.15) (2.20, 2.58) (1.28, 1.93) (1.06, 1.15) (2.20, 2.58) (1.28, 1.93) (1.28, 1

Note: The mortality rate is per 100,000 person-years and is age-standardized based on the 7th National Population Census data (2020). HRs were stratified by age-at-risk (in 5-year intervals), sex, and study areas, and adjusted for education, occupation, household income, marital status, alcohol consumption, smoking status, passive smoking status, physical activity levels, cooking and heating fuel usage, and consumption frequency of fresh fruits, fresh vegetables, meat, general obesity, and abdominal obesity. For cause-specific mortality, a proportional subdistribution hazards regression model was fitted to account for competing risks from other causes.

Abbreviation: PRISm=preserved ratio impaired spirometry; HR=hazard ratio; *Cl*=confidence interval.